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ABSTRACT 
Onset of Analgesia and Analgesic Efficacy of 
Tramadol/Acetaminophen and 
Codeine/Acetaminophen/Ibuprofen                  
in Acute Postoperative Pain:                        
A Single-Center, Single-Dose, Randomized,       
Active-Controlled, Parallel-Group Study                    
in a Dental Surgery Pain Model 
 
Background: The combination of tramadol and acetaminophen has demonstrated good 
efficacy in various clinical pain models. However, there is a need for comparisons of the 
onset of analgesia and other measures of analgesic efficacy with this combination and 
other strong combination analgesics for the management of acute pain. 
Objective: The goal of this study was to compare the time to onset of analgesia and other 
measures of analgesic efficacy with tramadol/acetaminophen 75/650 mg (Tr/Ac) and 
codeine/acetaminophen/ibuprofen 20/500/400 mg (Co/Ac/Ib) in the management of acute 
pain after oral surgery. 
Methods: This was a single-center, single-dose, randomized, active-controlled, parallel-
group study in healthy subjects who had undergone surgical extraction of ≥1 impacted 
third molar requiring bone removal. When patients reported at least moderate pain after 
dental surgery (score ≥5 on a 10-point scale), they were randomized to 1 of 2 treatment 
groups. The time to onset of analgesia was measured using a 2-stopwatch technique. The 
v 
times to the onset of perceptible and meaningful pain relief, pain intensity, pain relief, 
patient's overall assessment, and adverse events were recorded for 6 hours after dosing. 
Results: One hundred twenty-eight subjects participated in the study, 64 in each treatment 
group. The 2 groups were similar in terms of baseline pain severity and demographic 
characteristics (mean age, 23.7 and 23.4 years in the Tr/Ac and Co/Ac/Ib groups, 
respectively; mean body weight, 58.5 and 60.3 kg). The median times to the onset of 
perceptible pain relief were a respective 21.0 and 24.4 minutes, and the median times to 
the onset of meaningful pain relief were 56.4 and 57.3 minutes. Mean total pain relief and 
the sum of pain intensity difference were also similar in the early period after dosing (0–4 
hours). However, between 4 and 6 hours, Co/Ac/Ib was associated with significant 
differences in both variables compared with Tr/Ac (P < 0.05). Although similar through 
the 4-hour assessment, mean pain intensity difference was significantly greater with 
Co/Ac/Ib at 5 and 6 hours. The proportion of the patients assessing their assigned 
treatment as good or better was significantly greater with Co/Ac/Ib compared with Tr/Ac 
(P < 0.05). The safety profile of Tr/Ac was comparable to that of Co/Ac/Ib. 
Conclusions: In this small and selected group of subjects, the onset of analgesia and 
analgesic efficacy of Tr/Ac was comparable to that of Co/Ac/Ib. Tr/Ac provided rapid 
and effective analgesia for acute postoperative dental pain in this population. 
 
 
 
 
Key words: onset of analgesia, analgesic combination, analgesic efficacy, 
tramadol/acetaminophen, postoperative pain.
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INTRODUCTION 
To reduce the occurrence of adverse events (AEs) associated with the use of opioid 
analgesics, these agents have been combined with nonopioid agents such as 
２ 
acetaminophen to lower the amount of opioid needed to produce an equivalent degree of 
analgesia.1,2 Such combination products also have been claimed to produce a synergistic 
analgesic effect.1,2 
 Tramadol plus acetaminophen is one such analgesic combination.1 Tramadol 
hydrochloride, which has weak opioid activity, produces analgesia through an opioid 
effect that binds mu-opioid receptors and modifies transmission of pain signals through 
inhibition of serotonin and norepinephrine reuptake within pain pathways of the central 
nervous system.1,3,4 Clinical experience indicates that tramadol is associated with fewer 
adverse effects than typical opioid, notably respiratory depression, constipation, and 
potential for addiction.1,3,4 Furthermore, tramadol has been reported to be effective for 
various types of postoperative pain, including dental pain.5–7 Acetaminophen, on the other 
hand, produces analgesia by elevating the pain threshold through inhibition of N-methyl-
D-asparate– or substance P–mediated nitric oxide synthesis and/or inhibition of 
prostaglandin E2 release in the central nervous system.1,8,9 Acetaminophen, which has 
excellent antipyretic-effectiveness and safety profiles, has been available for ~40 
years.1,8,9 
 In animal models, the combination of tramadol and acetaminophen in 
approximately a 1:8 milligram ratio has been reported to result in synergistic analgesia.10 
Clinical studies have reported that the combination of tramadol/acetaminophen 37.5/325 
mg was effective and well tolerated in patients with dental pain,11,12 osteoarthritis flare 
pain,13 chronic back and joint pain,14,15 and fibromyalgia.16 This combination has 
demonstrated comparable efficacy and tolerability to the combination of 
hydrocodone/acetaminophen12 and codeine/acetaminophen.14 
３ 
 Use of the combination of codeine phosphate/acetaminophen/ibuprofen 
10/250/200 mg, which is not available in the United States, has been reported to provide 
good pain relief with no severe AEs in patients with chronic osteoarthritis (n=25)17 and in 
the dental pain model (n=25).18 Codeine is an opioid analgesic and relieves mild to 
moderate pain by binding to stereospecific opioid receptors in the central nervous system, 
altering processes affecting perception of and emotional response to pain.19 Codeine is 
converted to the more active drug morphine; however, this conversion is not equal in all 
patients or ethnic groups. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) 
with analgesic and antipyretic effects.1,19 It inhibits the activity of the enzyme 
cyclooxygenase, resulting in decreased formation of the prostaglandin and thromboxane 
precursors of arachidonic acid.19 
 In acute pain, a rapid onset of pain relief is desirable.20,21 Comparisons of the 
onset of analgesia and analgesic efficacy of tramadol/acetaminophen and other strong 
analgesic combinations in acute pain are necessary. To our knowledge, the time of onset 
of the analgesic effect of codeine/acetaminophen/ibuprofen has not been reported. 
Therefore, the purpose of this study was to compare the time to onset of analgesia and 
other measures of analgesic efficacy with tramadol/acetaminophen 75/650 mg (Tr/Ac) 
and codeine/acetaminophen/ibuprofen 20/500/400 mg (Co/Ac/Ib) in the treatment of 
acute pain after oral surgery. The surgical extraction of impacted mandibular third molars, 
a common oral surgical procedure, induces acute moderate to severe pain and has been 
used as a model for the effectiveness of analgesic agents by numerous 
investigators.2,12,13,18 
 
 
４ 
PATIENTS AND METHODS 
Inclusion and Exclusion Criteria 
 Healthy men and women aged ≥16 years with moderate or severe pain (score ≥5 
on a 10-point scale with 0 signifying no pain) resulting from oral surgery involving 
bilateral extraction of >2 third molars, one of which was at least a partial bony mandibular 
impaction requiring bone removal, were eligible for participation. Bone removal was 
considered necessary to ensure adequate postoperative pain intensity. The procedure 
involved 1 day of hospitalization. Women of childbearing potential had to have a negative 
urine pregnancy test result on the day of receiving study medication. All patients had to 
be sufficiently alert to understand and communicate with the study observer and be able 
to carry out the study procedures. 
 Patients were excluded if they had received or used another experimental drug or 
medical device within 30 days before screening; had received any analgesic medication 
other than short-acting preoperative or intraoperative anesthetic agents within 12 hours 
before receiving study medication; had taken any long-acting NSAID within 3 days 
before receipt of study medication; received any other analgesic medication after 
completion of oral surgery; had a history of seizure; had a history of drug and/or alcohol 
abuse within the past 6 months; had taken monoamine oxidase inhibitors, tricyclic 
antidepressants, neuroleptics, or other drugs that reduce the seizure threshold within 4 
weeks of study participation; had renal or hepatic dysfunction; were sensitive or allergic 
to tramadol, acetaminophen, codeine, ibuprofen, or other NSAIDs or aspirin; had peptic 
ulcer disease; had taken any selective serotonin reuptake inhibitors, diet pills, or 
methylphenidate within 4 weeks of study participation; or were at risk based on the 
５ 
precautions, warnings, and contraindications in the package inserts for Tr/Ac22 and 
Co/Ac/Ib.19  
 Before patients entered the study, the investigators obtained a medical history and 
performed a screening physical examination. After being informed of the nature of the 
study, all patients or the legal representatives of children aged <18 years signed a written 
informed consent form that had been approved by the institutional review board. 
 
Study Design 
 This was a single-center, single-dose, randomized, active-controlled, parallel-
group study. Patients undergoing >1 surgical extraction of an impacted third molar 
requiring bone removal were enrolled over 6 months at the Department of Oral and 
Maxillofacial Surgery, Dental College Hospital, Yonsei University, Seoul, Korea. The 
surgery was performed under local anesthesia with 2% lidocaine. The surgeon rated the 
surgical trauma as mild, moderate, or severe. 
 When patients reported moderate or severe pain after oral surgery, they were 
assigned to 1 of 2 treatment groups based on a randomization code. Single oral doses of 
the assigned study drugs were packaged in identical containers containing either Tr/Ac or 
Co/Ac/Ib and administered to each patient. The 2 products were not physically identical. 
 The study coordinator instructed patients in the use of the stopwatches and 
assessment scales. During the 6 hours after administration of study medication, the study 
coordinator recorded patients' assessments on case-report forms in the day-hospitalization 
ward. If the response to study drug was inadequate or there was no analgesic response, 
supplemental analgesia was available in the form of mefenamic acid 500 mg. 
 
６ 
Outcome Measures 
 The time to onset of analgesia was measured using a 2-stopwatch technique. Two 
stopwatches were activated when the study drug was administered. At the onset of 
perceptible pain relief, the patient stopped the first watch. At the onset of meaningful pain 
relief, the patient stopped the second watch. The study coordinator recorded the elapsed 
times shown on the watches on patient’s charts and case-report forms. 
 Additional measures of analgesic efficacy included pain intensity, pain relief, use 
of supplemental analgesic medication, and the patient's overall assessment. When the 
patient complained of moderate or severe pain (time zero), the baseline pain intensity 
score was recorded on the 10-point pain scale. The patient subsequently assessed his or 
her current pain using the same scale and pain relief from baseline at 30 minutes and 1, 2, 
3, 4, 5, and 6 hours after receiving study medication. A 6-hour assessment period was 
used because of the dosing instructions for Tr/Ac22 (2 tablets q4–6 h) and Co/Ac/Ib19 (1 
or 2 capsules q4h). Pain relief was rated on a 5-point scale (0 = none, 1 = a little, 2 = 
some, 3 = a lot, 4 = complete). At the end of the observation period or at withdrawal from 
the study, patients completed an overall assessment of study medication using a 5-point 
scale (1 = excellent, 2 = very good, 3= good, 4 = fair, 5 = poor). 
 When patients took supplemental analgesic medication, they were discontinued 
from the study, and the study coordinator recorded the time, dose of rescue medication, 
and all other efficacy assessments at the time of withdrawal. 
 Further efficacy assessments included total pain relief (TOTPAR), derived from 
the sum of recorded pain relief scores; pain intensity difference (PID), calculated by 
subtracting each recorded pain intensity score from the baseline pain intensity score; and 
sum of pain intensity difference (SPID), computed by adding the calculated PID scores. 
７ 
 The safety profiles of the study treatments were assessed based on AEs reported 
by patients during the observation period. An AE was defined as any unfavorable and 
unintended sign, symptom, or disease temporarily associated with the use of an 
investigational product. Such surgical consequences as dry sockets, surface ostitis, 
ecchymosis, edema, infection, and paresthesia were not recorded as AEs, because these 
consequences do not appear in the immediate postoperative period. Blinded study 
investigators judged and recorded the relationship between the study therapies and the 
reported AEs. 
 
Statistical Analysis 
 The study was designed to include 128 qualified patients randomly assigned to 1 
of 2 treatment groups. The comparability of the demographic and baseline characteristics 
of the 2 treatment groups was tested using the chi-square test or Fisher exact test for 
categorical variables (eg, sex) and the t test for continuous variables (eg, age). 
 Efficacy analyses were performed using last-observation-carried-forward 
methodology. Time to the onset of perceptible pain relief and time to the onset of 
meaningful pain relief were summarized using medians (95% CIs) and means (SDs) and 
assessed using the Wilcoxon rank sum test and the t test. Kaplan-Meier curves were 
generated for the rates of pain relief and meaningful pain relief in each group and 
compared using the log-rank test. Mean TOTPAR and SPID scores were computed for 
the intervals from 0 to 2 hours, 2 to 4 hours, and 4 to 6 hours. Between-group differences 
were tested using the Wilcoxon rank sum test. 
８ 
 For the safety-profile analysis, only those signs and symptoms that emerged 
during the study were summarized for the 2 groups. Between-group differences in the 
incidence of drug-related AEs were assessed using the Fisher exact test. 
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RESULTS 
Demographic and Baseline Characteristics 
Table I. Demographic characteristics and baseline pain intensity.  
 
Characteristic 
Tr/Ac 
(n = 64) 
Co/Ac/Ib 
(n = 64) 
Sex 
   Female 
   Male 
 
37 
27 
 
39 
25 
Age, y 
   Mean 
   Range 
 
23.4 
16–40 
 
23.7 
17–37 
Body weight, kg 
   Mean 
   Range 
 
58.5 
30–98 
 
60.3 
44–100 
Height, cm 
   Mean 
   Range 
 
166.8 
150–188 
 
167.3 
155–187 
Baseline pain score* 
   5 
   6 
   7 
   8 
   Mean (SD) 
 
28 
19 
11 
6 
5.92 (1.00) 
 
28 
27 
6 
3 
5.75 (0.82) 
１０ 
Tr/Ac = tramadol/acetaminophen 75/650 mg; Co/Ac/Ib = 
codeine/acetaminophen/ibuprofen 20/500/400 mg. 
*10-point rating scale. 
 
 One hundred and twenty-eight patients were enrolled in the trial and randomized 
equally to the 2 treatment groups. All patients were Asian Koreans, and were similar in 
terms of sex, age, body weight, height, and surgical characteristics (Tables I and II). 
Mean (SD) baseline pain scores were 5.92 (1.00) in the Tr/Ac group and 5.75 (0.82) in 
the Co/Ac/Ib group. Bilateral extraction of mandibular third molars, not including a 
maxillary tooth, was the most common type of oral surgery in this trial (Table II). The 
surgical trauma rating was mainly moderate (46.8% Tr/Ac, 50.0% Co/Ac/Ib). 
 Two patients in the Tr/Ac group took supplemental analgesia within the 6-hour 
observation period and were withdrawn from the study at the time of receiving 
supplemental medication. Another 2 patients in the same group reported perceptible pain 
relief but did not experience meaningful pain relief. Last-observation-carried-forward 
methodology was used in these 4 patients. 
 
Times to Onset of Pain Relief 
 Table III summarizes the median and mean times to the onset of perceptible and 
meaningful pain relief. The median times to the onset of perceptible pain relief were 21.0 
minutes (95% CI, 17.1–25.0) in the Tr/Ac group and 24.4 minutes (95% CI, 21.0–27.7) in 
the Co/Ac/Ib group. The median times to the onset of meaningful pain relief were a 
respective 56.4 minutes (95% CI, 48.7–64.1) and 57.3 minutes (95% CI, 51.5–63.0). The 
differences between groups were not statistically significant (Figures 1 and 2). The mean 
１１ 
(SD) times to the onset of perceptible pain relief were 26.9 (16.1) minutes in the Tr/Ac 
group and 25.0 (13.7) minutes in the Co/Ac/Ib group. The corresponding mean times to 
the onset of meaningful pain relief were 66.3 (31.3) and 57.0 (23.6) minutes. Again, the 
differences between groups were not statistically significant. 
 
Table II. Surgical characteristics. 
 Tr/Ac 
(n = 64) 
Co/Ac/Ib 
(n = 64) 
No. (%) of teeth extracted 
  2* 
  3 
  4 
 
37 (57.8) 
13 (20.3) 
14 (21.9) 
 
36 (56.3) 
7 (10.9) 
21 (32.8) 
No. (%) of bony extractions 
  1 
  2 
  3 
  4 
 
3 (5.7) 
59 (92.2) 
2 (3.1) 
0 
 
0 
58 (90.6) 
4 (6.3) 
2 (3.1) 
Surgical trauma rating, no. 
(%) of patients 
  Mild 
  Moderate 
  Severe 
 
 
17 (26.6) 
30 (46.8) 
17 (26.6) 
 
 
14 (21.9) 
32 (50.0) 
18 (28.1) 
*Bilateral extraction of mandibular third molars. 
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Table III. Summary of median and mean times to the onset of perceptible and 
meaningful pain relief. 
 Tr/Ac 
(n = 64) 
Co/Ac/Ib 
(n = 64) 
Onset of perceptible pain 
relief, min 
  Median (95% CI) 
  Mean (SD) 
 
 
21.0 (17.1–25.0) 
26.9 (16.1) 
 
 
24.4 (21.0–27.7) 
25.0 (13.7) 
Onset of meaningful pain 
relief, min 
  Median (95% CI) 
  Mean (SD) 
 
 
56.4 (48.7–64.1) 
66.3 (31.3) 
 
 
57.3 (51.5–63.0) 
57.0 (23.6) 
 
Figure 1. Kaplan-Meier curve for the cumulative probability of attaining 
onset of perceptible pain relief in the tramadol/acetaminophen (Tr/Ac) and 
codeine/acetaminophen/ibuprofen (Co/Ac/Ib) groups. 
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Figure 2. Kaplan-Meier curve for the cumulative probability of attaining 
onset of meaningful pain relief in the tramadol/acetaminophen (Tr/Ac) and 
codeine/acetaminophen/ibuprofen (Co/Ac/Ib) groups. 
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Other Efficacy Analyses 
 The time-effect curve for PID during the 6-hour observation period is shown in 
Figure 3. From 0.5 to 4 hours, the 2 drugs had similar effects. However, at the 5- and 6-
hour assessments, PID was significantly greater with Co/Ac/Ib compared with Tr/Ac (P < 
0.05). 
 For TOTPAR and SPID, the differences between the 2 groups were not 
significant during the first 2 time intervals (0–2 and 2–4 hours). However, during the last 
interval (4–6 hours), both values were significantly greater with Co/Ac/Ib compared with 
Tr/Ac (P < 0.05). Mean (SD) peak PID values were 4.4 (1.18) and 4.8 (0.9) in the Tr/Ac 
and Co/Ac/Ib groups, respectively, a nonsignificant difference. Peak pain relief values 
were almost identical in the 2 groups (Table IV). 
１４ 
 In the Tr/Ac group, 90.6% of patients gave an overall assessment of their 
assigned treatment as good or better, whereas 100% of the Co/Ac/Ib group gave such an 
assessment (P < 0.05) (Figure 4). 
 
Figure 3. Time-effect curves for mean hourly pain intensity difference (PID) 
in the tramadol/acetaminophen (Tr/Ac) and codeine/acetaminophen/ibuprofen 
(Co/Ac/Ib) groups. *P < 0.05, Wilcoxon rank sum test. 
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Safety Profile 
 Two of 64 patients (3.1%) who received Tr/Ac reported AEs (dizziness and 
nausea). One of these patients reported both AEs simultaneously. In the investigator's 
judgment, a correlation between the nausea and study medication was unlikely. The 
Co/Ac/Ib group reported no AEs. No severe AEs occurred in either group during this 
study. 
*
*
１５ 
Table IV. Total pain relief (TOTPAR), sum of pain intensity difference (SPID), 
peak pain relief (PR), and peak pain intensity difference (PID). Values are mean 
(SD).  
 
Measure/Time Point 
Tr/Ac 
(n = 64) 
Co/Ac/Ib 
(n = 64) 
TOTPAR 
  0–2 Hours 
  2–4 Hours 
  4–6 Hours 
 
6.4 (1.84) 
5.8 (0.74) 
5.0 (1.28)* 
 
6.9 (1.48) 
6.1 (0.60) 
5.7 (0.77)* 
SPID 
  0–2 Hours 
  2–4 Hours 
  4–6 Hours 
 
7.9 (2.98) 
8.1 (2.27) 
6.8 (2.68)* 
 
8.8 (2.79) 
8.8 (1.92) 
8.2 (2.11)* 
Peak PR 3.1 (0.37) 3.1 (0.33) 
Peak PID 4.4 (1.18) 4.8 (0.9) 
*P < 0.05, Wilcoxon rank sum test. 
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Figure 4. Patients' overall assessment of study medication. The proportion of 
patients assessing treatment as good or better was significantly greater in the 
codeine/acetaminophen/ibuprofen group compared with the 
tramadol/acetaminophen group (100% vs 90.6%, respectively; P < 0.05, Fisher exact 
test).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 9.4%     25.0%              50.0%             15.6% 
6.3%           60.9%                      32.8%
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DISCUSSION 
This study found no difference in the median time to the onset of perceptible pain relief 
between groups. The 21-minute median time to the onset of perceptible pain relief with 
Tr/Ac was shorter than the 34 minutes reported by Fricke et al,12 who used the same dose 
of Tr/Ac in the dental pain model, and slightly longer than the 17 minutes reported by 
Medve et al,11 who also reported much longer times to the onset of perceptible pain relief 
with ibuprofen (34 minutes) and tramadol alone (51 minutes) and a similar time of onset 
with acetaminophen alone (18 minutes).11 That study and another by Moller et al20 
demonstrated that acetaminophen had a rapid onset of action. In our study, in which 
acetaminophen was a component in both study treatments, the times to the onset of 
meaningful pain relief were similar between groups. 
 Given a rapid onset of analgesia, other efficacy variables help characterize the 
early effects of a drug in the period after drug administration.20,21 In the present study, 
TOTPAR, PID, and SPID values were similar between groups in the early period after 
administration (0–4 hours), a finding that was consistent with the onset of pain relief. 
Peak pain relief and peak PID were also similar in the 2 groups. However, between 4 and 
6 hours after drug administration, TOTPAR and SPID values were significantly greater 
for Co/Ac/Ib compared with Tr/Ac (P < 0.05). Similarly, although there were no 
statistical differences in PID values until the 4-hour assessment, Co/Ac/Ib became 
significantly superior to Tr/Ac at the 5- and 6-hour assessment (P < 0.05).  
 The anti-inflammatory action of the ibuprofen component of Co/Ac/Ib was 
thought to be the reason for the latter results. Many factors in the pain that develops after 
surgical extraction of impacted third molars relate to the peripheral inflammatory reaction 
initiated by surgical trauma. Therefore, NSAIDs such as ibuprofen and ketorolac have 
１８ 
been reported to be effective for postoperative pain.23–25 A 6-hour assessment was used in 
the present study because of the recommended dosing of the 2 drugs19,22; other studies of 
the onset of analgesia have used similar observation periods (420 and 621 hours). Thus, the 
significant between-group differences in TOTPAR and SPID from 4 to 6 hours should not 
be the effect of the short assessment period.  
 Use of Tr/Ac has been associated with dizziness, headache, nausea, vomiting, 
somnolence, and constipation,11–16,24 with dizziness and nausea being the most commonly 
reported AEs (up to 20% and 23% of patients, respectively).11–16 In the present study, only 
2 patients (3.1%) in the Tr/Ac group reported dizziness and nausea, an extremely low 
incidence compared with previous reports.11–16,24 Although a potential for seizures is 
known to be associated with tramadol, no severe AEs occurred during this study. 
Tramadol has a favorable safety profile compared with traditional opioids, and 
acetaminophen is useful in cases in which NSAIDs are contraindicated (eg, peptic or 
gastric ulcer).1,26 Therefore, Tr/Ac may offer good efficacy with a good safety profile 
relative to the combination of Co/Ac/Ib, which includes a traditional opioid and an 
NSAID. 
 
 
 
 
 
 
 
 
１９ 
CONCLUSIONS 
In this study, the times to the onset of perceptible and meaningful relief of acute dental 
pain did not differ significantly between Tr/Ac and Co/Ac/Ib. TOTPAR, SPID, and PID 
were similar between treatments in the early observation period (0–4 hours), although the 
difference in TOTPAR and SPID favored Co/Ac/Ib from 4 to 6 hours after administration, 
and the mean PID was significantly greater with Co/Ac/Ib at 5 and 6 hours. Both 
treatments were well tolerated in the population studied. Although the inclusion criteria 
limit extrapolation of the findings of this study to the general population or to other pain 
models in which bone pain is not present, the results in this population suggest that Tr/Ac 
provides rapid and effective analgesia in the management of acute postoperative pain. 
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ABSTRACT in Korean 
수술후 급성 동통에 대한 
Tramadol/Acetaminophen 과 
Codeine/Acetaminophen/Ibuprofen 의             
효과 발현시점과 진통효과의 비교 
 
연세대학교 대학원 치의학과 
정 영 수 
<지도교수 이 의 웅> 
 
연구배경: tramadol 과 acetaminophen 복합제제는 다양한 통증 임상 
시험에서 좋은 효과를 보여왔지만 급성 통증 상태에서 이 복합제제와 강력한 
진통제라고 알려진 다른 진통제의 효과 발현 시점과 진통효과를 비교하는 
것이 필요하다고 생각되었다. 
연구목적: 본 연구의 목적은 구강 수술후 급성 동통의 치료에서 75 ㎎ 
tramadol/650 ㎎ acetaminophen (Tr/Ac) 복합제제와 20 ㎎ codeine/500 
㎎ acetaminophen/400 ㎎ ibuprofen (Co/Ac/Ib) 복합제제의 효과발현 
시점과 다른 진통효과를 비교하고자 하였다. 
２５ 
연구방법: 이 연구는 무작위, 1 회 투여, 평행그룹 디자인으로, 단일 센터에서 
실시한 비교 임상시험이었으며, 골삭제를 필요로 하는 하나 이상의 하악 매복 
제 3 대구치 외과적 발거 수술을 시행 받는 건강한 환자들을 대상으로 하였다. 
구강 수술 후 피험자가 중등도 또는 심도의 통증을 호소하였을 때(통증 
평가를 위한 10 단계 순위에서 5 점 이상), 각 피험자는 무작위 배정 방법에 
따라 두 군 중의 한 군에 할당되었다. 시험 약 투여 후 6 시간 동안 지각할 
수 있는 통증 완화시점과 의미있는 통증완화시점은 2 개의 stopwatch 방법을 
이용하여 측정하였고, 그 외 통증 강도, 통증 완화 정도, 전반적 평가, 이상 
반응 등을 기록하였다. 
연구결과: 128 명의 한국인 환자가 이 시험에 등록되어 같은 수(64 명씩)로 
두 군에 무작위로 할당되었는데, 성별, 나이, 체중, 신장 같은 인구통계학적 
기초 자료뿐만 아니라 두 군의 수술 특징도 서로 유사하였다. 지각할 수 있는 
통증 완화시점의 중간값(median)은 Tr/Ac 군과 Co/Ac/Ib 군이 각각 21.0 
분과 24.4 분이었고, 의미있는 통증완화시점의 중간값(median)은 56.4 분과 
57.3 분이었으며, 이들은 통계적으로 유사하였다. 전체 통증 
완화정도(TOTPAR)와 최초 통증에 대한 통증 강도 차이의 합(SPID) 같은 
다른 효과 변수들은 처음 2 번의 시간 구간 동안(0-2 시간과 2-4 시간)에선 
두 군간의 차이가 유의하지 않았지만 마지막 시간 구간인 4-6 시간에선 
통계적으로 유의 있는 차이가 발견되었다(P < 0.05). 시간별 
통증강도차이(PID)도 0.5 에서 4 시간까지 두 약제는 비슷한 효과를 보였으나, 
5 시간과 6 시간째 측정치에서 Co/Ac/Ib 군이 더 좋았다. 환자의 전반적인 
２６ 
평가에서 “좋음” 이상으로 평가한 것도 Co/Ac/Ib 군이 Tr/Ac 군보다 
유의있게 많았다. Tr/Ac 의 안정성은 Co/Ac/Ib 과 통게적으로 유사하였다. 
결론: 이번 구강 수술 후 급성 통증의 치료에서 Tr/Ac 의 통증완화시점이 
Co/Ac/Ib 의 통증완화시점과 차이가 없었으며 다른 진통 효과 변수들도 약물 
투여 후 조기에는 유사하였다. 따라서 Tr/Ac 은 수술 후 급성 통증의 빠르고 
효과적인 치료를 위해 추천할 만 하다고 사료되었다.  
 
핵심되는 단어: 통증완화시점, 진통제 복합제제, 진통 효과, 
tramadol/acetaminophen, 수술후 통증 
 
